Literature DB >> 17020958

Gender dictates the nuclear receptor-mediated regulation of CYP3A44.

Sayeepriyadarshini Anakk1, Wendong Huang, Jeffrey L Staudinger, Kheng Tan, Timothy J Cole, David D Moore, Henry W Strobel.   

Abstract

The CYP3As are broad-spectrum drug-metabolizing enzymes that are collectively responsible for more than 50% of xenobiotic metabolism. Unlike other CYP3As, murine CYP3A44 is expressed predominantly in the female liver, with much lower levels in male livers and no detectable expression in brain or kidney in either gender. In this study, we examined the role of nuclear hormone receptors in the regulation of Cyp3a44 gene expression. Interestingly, we observed differential effects of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) -mediated activation of Cyp3a44 gene expression, which was gender-specific. For example, activation of PXR by pregnenolone-16alpha-carbonitrile (PCN) and dexamethasone (DEX) induced CYP3A44 mRNA levels in a PXR-dependent fashion in male mice, whereas no induction was detected in female mice. In contrast, PCN and DEX down-regulated CYP3A44 expression in female PXR null animals. Similar to PXR, CAR activation also showed a male-specific induction with no effect on CYP3A44 levels in females. When PXR knockout mice were challenged with the CAR activator phenobarbital, a significant up-regulation of male CYP3A44 levels was observed, whereas levels in females remained unchanged. We conclude that gender has a critical impact on PXR- and CAR-mediated effects of CYP3A44 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020958     DOI: 10.1124/dmd.106.011270

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation.

Authors:  J P Hernandez; L C Mota; W S Baldwin
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-06-01

2.  Nuclear receptor CAR specifically activates the two-pore K+ channel Kcnk1 gene in male mouse livers, which attenuates phenobarbital-induced hepatic hyperplasia.

Authors:  Kosuke Saito; Rick Moore; Masahiko Negishi
Journal:  Toxicol Sci       Date:  2013-01-04       Impact factor: 4.849

3.  Breast cancer-resistance protein (BCRP1) in the fetal mouse brain: development and glucocorticoid regulation.

Authors:  Sophie Petropoulos; William Gibb; Stephen G Matthews
Journal:  Biol Reprod       Date:  2010-12-15       Impact factor: 4.285

4.  A high-fat high-energy diet influences hepatic CYP3A expression and activity in low-birth-weight developing female rats.

Authors:  Shao-Qing Ni; Yin Lou; Xiu-Min Wang; Zheng Shen; Jue Wang; Zheng-Yan Zhao; Su Zeng
Journal:  World J Pediatr       Date:  2016-06-30       Impact factor: 2.764

5.  Hepatic CYP3A expression and activity in low birth weight developing female rats.

Authors:  Zhi-Wei Zhu; Shao-Qing Ni; Xiu-Min Wang; Jue Wang; Su Zeng; Zheng-Yan Zhao
Journal:  World J Pediatr       Date:  2013-08-09       Impact factor: 2.764

6.  Synergistic Antitumorigenic Activity of Calcitriol with Curcumin or Resveratrol is Mediated by Angiogenesis Inhibition in Triple Negative Breast Cancer Xenografts.

Authors:  Janice García-Quiroz; Rocío García-Becerra; Clara Santos-Cuevas; Gerardo J Ramírez-Nava; Gabriela Morales-Guadarrama; Nohemí Cárdenas-Ochoa; Mariana Segovia-Mendoza; Heriberto Prado-Garcia; David Ordaz-Rosado; Euclides Avila; Andrea Olmos-Ortiz; Sofía López-Cisneros; Fernando Larrea; Lorenza Díaz
Journal:  Cancers (Basel)       Date:  2019-11-06       Impact factor: 6.639

7.  The Mouse Microbiome Is Required for Sex-Specific Diurnal Rhythms of Gene Expression and Metabolism.

Authors:  Benjamin D Weger; Cédric Gobet; Jake Yeung; Eva Martin; Sonia Jimenez; Bertrand Betrisey; Francis Foata; Bernard Berger; Aurélie Balvay; Anne Foussier; Aline Charpagne; Brigitte Boizet-Bonhoure; Chieh Jason Chou; Felix Naef; Frédéric Gachon
Journal:  Cell Metab       Date:  2018-10-18       Impact factor: 27.287

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.